Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jørgensen, Marit Eika"'
Autor:
Færch K; Steno Diabetes Center Copenhagen, Gentofte, Denmark.; Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark., Amadid H; Steno Diabetes Center Copenhagen, Gentofte, Denmark., Bruhn L; Steno Diabetes Center Copenhagen, Gentofte, Denmark., Clemmensen KKB; Steno Diabetes Center Copenhagen, Gentofte, Denmark., Hulman A; Steno Diabetes Center Aarhus, Aarhus, Denmark., Ried-Larsen M; Centre for Physical Activity Research, Rigshospitalet, Copenhagen, Denmark.; Institute of Sports and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark., Blond MB; Steno Diabetes Center Copenhagen, Gentofte, Denmark.; Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark., Jørgensen ME; Steno Diabetes Center Copenhagen, Gentofte, Denmark.; University of Southern Denmark, Copenhagen, Denmark., Vistisen D; Steno Diabetes Center Copenhagen, Gentofte, Denmark.; Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
Publikováno v:
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Oct 05; Vol. 12, pp. 753810. Date of Electronic Publication: 2021 Oct 05 (Print Publication: 2021).
Autor:
Hansen CS; Steno Diabetes Center Copenhagen, Gentofte, Denmark christian.stevns.hansen@regionh.dk., Færch K; Steno Diabetes Center Copenhagen, Gentofte, Denmark., Jørgensen ME; Steno Diabetes Center Copenhagen, Gentofte, Denmark.; National Institute of Public Health, Southern Denmark University, Odense, Denmark., Malik M; National Heart and Lung Institute, Imperial College, London, U.K., Witte DR; Department of Public Health, Aarhus University, Aarhus, Denmark.; Danish Diabetes Academy, Odense, Denmark., Brunner EJ; Department of Epidemiology and Public Health, University College London, London, U.K., Tabák AG; Department of Epidemiology and Public Health, University College London, London, U.K.; Faculty of Medicine, Semmelweis University, Budapest, Hungary., Kivimäki M; Department of Epidemiology and Public Health, University College London, London, U.K., Vistisen D; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
Publikováno v:
Diabetes care [Diabetes Care] 2019 May; Vol. 42 (5), pp. 867-874. Date of Electronic Publication: 2019 Apr 02.
Autor:
Færch K; Steno Diabetes Center Copenhagen, 2820 Gentofte, Denmark., Witte DR; Department of Public Health, Aarhus University, 8000 Aarhus, Denmark.; Danish Diabetes Academy, 5000 Odense, Denmark., Brunner EJ; Department of Epidemiology and Public Health, University College London, London WC1E 6BT, United Kingdom., Kivimäki M; Department of Epidemiology and Public Health, University College London, London WC1E 6BT, United Kingdom., Tabák A; Department of Epidemiology and Public Health, University College London, London WC1E 6BT, United Kingdom.; First Department of Medicine, Faculty of Medicine, Semmelweis University, 1083 Budapest, Hungary., Jørgensen ME; Steno Diabetes Center Copenhagen, 2820 Gentofte, Denmark.; National Institute of Public Health, Southern Denmark University, 1353 Copenhagen, Denmark., Ekelund U; Department of Sport Medicine, Norwegian School of Sport Sciences, 0806 Oslo, Norway.; Norwegian Institute of Public Health, 0403 Oslo, Norway., Vistisen D; Steno Diabetes Center Copenhagen, 2820 Gentofte, Denmark.
Publikováno v:
The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2017 Oct 01; Vol. 102 (10), pp. 3712-3721.
Autor:
Kosiborod M; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.). mkosiborod@saint-lukes.org., Cavender MA; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Fu AZ; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Wilding JP; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Khunti K; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Holl RW; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Norhammar A; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Birkeland KI; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Jørgensen ME; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Thuresson M; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Arya N; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Bodegård J; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Hammar N; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.)., Fenici P; From Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.); University of North Carolina, Chapel Hill (M.A.C.); Georgetown University Medical Center, Washington, DC (A.Z.F.); University of Liverpool, United Kingdom (J.P.W.); University of Leicester, United Kingdom (K.K.); University of Ulm, Germany (R.W.H.); Karolinska Institutet, Stockholm, Sweden (A.N., N.H.); University of Oslo, Norway (K.I.B.); Oslo University Hospital, Norway (K.I.B.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); National Institute of Public Health, Southern Denmark University, Copenhagen (M.E.J.); Statisticon AB, Uppsala, Sweden (M.T.); AstraZeneca, Gaithersburg, MD (N.A.); AstraZeneca, Oslo, Norway (J.B.); AstraZeneca Gothenburg, Sweden (N.H.); and AstraZeneca, Cambridge, United Kingdom (P.F.).
Publikováno v:
Circulation [Circulation] 2017 Jul 18; Vol. 136 (3), pp. 249-259. Date of Electronic Publication: 2017 May 18.
Autor:
Færch K; Steno Diabetes Center A/S, Niels Steensens Vej 2, 2820, Gentofte, Denmark, krif@steno.dk., Vistisen D, Johansen NB, Jørgensen ME
Publikováno v:
Current diabetes reports [Curr Diab Rep] 2014 Jun; Vol. 14 (6), pp. 493.
Autor:
Jørgensen ME; Steno Diabetes Centre, Gentofte, Denmark. maej@steno.dk, Bjerregaard P, Borch-Johnsen K, Witte D
Publikováno v:
The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2010 Nov; Vol. 95 (11), pp. E333-6. Date of Electronic Publication: 2010 Aug 25.
Autor:
Khunti, Kamlesh, Kosiborod, Mikhail, Kim, Dae Jung, Kohsaka, Shun, Lam, Carolyn S.P., Goh, Su Yen, Chiang, Chern En, Shaw, Jonathan, Cavender, Matthew A., Tangri, Navdeep, Franch-Nadal, Josep, Holl, Reinhard W., Jørgensen, Marit Eika, Norhammar, Anna, Eriksson, Johan G., Zaccardi, Francesco, Karasik, Avraham, Magliano, Dianna J., Thuresson, Marcus, Chen, Hungta, Wittbrodt, Eric, Bodegård, Johan, Surmont, Filip, Fenici, Peter, Wilding, John P., Carstensen, Bendix, Kendrick, Rachel, Belli, Wesley, Wittbrodt, Eric T., Noguchi, Yusuke, Andersson-Sundell, Karolina
Publikováno v:
Khunti, K, Kosiborod, M, Kim, D J, Kohsaka, S, Lam, C S P, Goh, S Y, Chiang, C E, Shaw, J, Cavender, M A, Tangri, N, Franch-Nadal, J, Holl, R W, Jørgensen, M E, Norhammar, A, Eriksson, J G, Zaccardi, F, Karasik, A, Magliano, D J, Thuresson, M, Chen, H, Wittbrodt, E, Bodegård, J, Surmont, F, Fenici, P, Kosiborod, M, Cavender, M A, Wilding, J P, Khunti, K, Norhammar, A, Carstensen, B, Holl, R W, Lam, C S P, Kendrick, R, Belli, W, Wittbrodt, E T, Franch-Nadal, J, Noguchi, Y, Karasik, A, Tangri, N, Kohsaka, S, Kim, D J, Shaw, J, Andersson-Sundell, K, Goh, S Y, Chiang, C E, Eriksson, J G, Zaccardi, F, Fenici, P, Bodegård, J & on behalf of the CVD-REAL Investigators and Study Group 2021, ' Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents : analysis of CVD-REAL data ', Cardiovascular Diabetology, vol. 20, no. 1, 159 . https://doi.org/10.1186/s12933-021-01345-z
Cardiovascular Diabetology, 20(1):159. BioMed Central Ltd.
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-15 (2021)
Cardiovascular Diabetology
CARDIOVASCULAR DIABETOLOGY
Cardiovascular Diabetology, 20(1):159. BioMed Central Ltd.
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-15 (2021)
Cardiovascular Diabetology
CARDIOVASCULAR DIABETOLOGY
Background Randomized, controlled cardiovascular outcome trials may not be fully representative of the management of patients with type 2 diabetes across different geographic regions. We conducted analyses of data from the multinational CVD-REAL cons
Autor:
Færch, Kristine, Witte, Rinse Daniel, Brunner, Eric John, Kivimäki, Mika, Tabak, Adam, Jørgensen, Marit Eika, Ekelund, Ulf, Vistisen, Dorte
Publikováno v:
Journal of Clinical Endocrinology and Metabolism
Færch, K, Witte, D R, Brunner, E J, Kivimäki, M, Tabák, A, Jørgensen, M E, Ekelund, U & Vistisen, D 2017, ' Physical Activity and Improvement of Glycemia in Prediabetes by Different Diagnostic Criteria ', Journal of Clinical Endocrinology and Metabolism, vol. 102, no. 10, pp. 3712-3721 . https://doi.org/10.1210/jc.2017-00990
Færch, K, Witte, D R, Brunner, E J, Kivimäki, M, Tabák, A, Jørgensen, M E, Ekelund, U & Vistisen, D 2017, ' Physical Activity and Improvement of Glycemia in Prediabetes by Different Diagnostic Criteria ', Journal of Clinical Endocrinology and Metabolism, vol. 102, no. 10, pp. 3712-3721 . https://doi.org/10.1210/jc.2017-00990
Context: The effects of physical activity (PA) on improvement of glycemia may differ between prediabetic individuals defined by oral glucose tolerance test vs glycated hemoglobin (HbA1c).Objective: We studied the association between PA and improvemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ca4461f61b25161ccd7cce0cef37e793
http://hdl.handle.net/11250/2465960
http://hdl.handle.net/11250/2465960